Latest 10-K annual reports

Oncotelic Therapeutics, Inc. (OTLC) filed its annual report for the fiscal year ended December 31, 2025, highlighting a significant increase in the fair value of its investment in its joint venture, GMP Biotechnology Limited (GMP Bio).

Hyperscale Data, Inc. filed its 2025 Form 10-K, detailing a complex financial year marked by strategic shifts, significant capital raises, and ongoing operational challenges across its diverse business segments.

Petros Pharmaceuticals has pivoted to a technology-focused business model following the insolvency of its legacy subsidiaries and the discontinuation of its Stendra product line.

Spindletop Oil & Gas Co. reports a net loss of $1.88 million for fiscal year 2025 amid rising operational costs and increased asset retirement obligations.

XMax Inc. reports 2025 annual results while announcing a strategic pivot into artificial intelligence infrastructure and services.

Selectis Health reports a net loss of $1.0 million for 2025 and highlights substantial doubt regarding its ability to continue as a going concern.

Healthcare Triangle, Inc. announced its annual report for the fiscal year ended December 31, 2025, detailing a 19% increase in revenue to $13.9 million, driven by growth in Software Services.

Eline Entertainment Group, Inc. remains a developmental stage company with no revenue, reporting a net loss of $44,992 for fiscal year 2025.

Aibotics, Inc. reports a net loss of $2.2 million for 2025 while pivoting its business focus toward AI-powered robotics and wellness products.

Citi Trends returned to profitability in fiscal 2025, reporting $5.2 million in net income driven by a 9.7% increase in comparable store sales.

TransCode Therapeutics, Inc. has entered into a significant equity issuance and registration rights agreement with Unleash Immuno Oncolytics, Inc., alongside a standby equity purchase agreement with YA II PN, LTD, bolstering its financial and strategic position.

Greenway Technologies, Inc. files its 2025 Form 10-K detailing its Gas-to-Liquids (GTL) technology development, ongoing financial challenges, and legal settlements.

Starfighters Space, Inc. filed its Form 10-K detailing its common stock, registered under Section 12 of the Securities Exchange Act of 1934, outlining shareholder rights, authorized capital, and outstanding warrants.

Hall Chadwick Acquisition Corp. filed its 2025 Annual Report, detailing its status as a blank check company and its recent non-binding letter of intent with REEcycle Holdings, Inc.

Northwest Biotherapeutics reports on its 2025 fiscal year, detailing operational progress, financial performance, and ongoing clinical development efforts for its DCVax therapies.

Western Uranium & Vanadium Corp. has filed its annual report for the fiscal year ended December 31, 2025, detailing operational progress, financial performance, and market outlook.

Constellation Acquisition Corp I has entered into a Business Combination Agreement with HiTech Minerals Inc., aiming for a merger expected in the second half of 2026.

CFN Enterprises Inc. files its 2025 Form 10-K, detailing strategic acquisitions in the wine sector, the discontinuation of its hemp operations due to new legislation, and ongoing financial challenges.

Sotherly Hotels Inc. outlines the material terms of its common and preferred stock, including ownership restrictions and voting rights, as part of its SEC filings.

Drugs Made In America Acquisition II Corp. (DMIIU) has filed its annual report for the fiscal year ended December 31, 2025, detailing its activities as a blank check company and outlining its strategy for a future business combination.

Gloo Holdings, Inc. announced a significant increase in total revenue for the fiscal year ended January 31, 2026, driven by strategic acquisitions and platform expansion.

Profusa, Inc. filed its annual report detailing 2025 financial performance, ongoing product development for biosensors, and significant challenges including Nasdaq listing compliance.

Arrive AI Inc. has formalized its commitment to ethical business practices and compliance with laws through its newly adopted Code of Business Conduct and Ethics.

Barfresh Food Group Inc. filed its annual 10-K report for the fiscal year ended December 31, 2025, detailing revenue growth driven by the Arps Dairy acquisition, alongside ongoing operational challenges and strategic financing.

CERo Therapeutics Holdings, Inc. outlines the material terms of its common and preferred stock, including various series of convertible preferred stock and outstanding warrants.

NetBrands Corp. details its strategic pivot to blockchain infrastructure and cryptocurrency mining for the fiscal year ended December 31, 2025, reporting significant revenue from mining operations.

Nu-Med Plus, Inc. files its annual report on Form 10-K for the fiscal year ended December 31, 2025, detailing its ongoing development of nitric oxide delivery systems and its precarious financial situation.

Splash Beverage Group's 2025 10-K reveals significant revenue decline and ongoing going concern issues, while pursuing a potential acquisition of Medterra CBD.

Kala Bio, Inc. announces a strategic pivot towards developing an AI infrastructure platform for the biotech industry, following the discontinuation of its KPI-012 biologics program.

Cenntro Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2025, detailing a significant decrease in revenue and a net loss, alongside strategic shifts in its distribution model and product development.